HIV infection alters SARS-CoV-2 responsive immune parameters but not clinical outcomes in COVID-19 disease
HIV infection alters SARS-CoV-2 responsive immune parameters but not clinical outcomes in COVID-19 disease
Abstract HIV infection alters the immune response and can compromise protective immunity to multiple pathogens following vaccination. We investigated the impact of HIV on the immune response to SARS-CoV-2 using longitudinal samples from 124 participants from KwaZulu-Natal, South Africa, an area of extremely high HIV prevalence. 44% of participants were people living with HIV (PLWH) and commonly had other co-morbidities, including obesity, hypertension, and diabetes. The majority of PLWH but not HIV negative participants showed CD8 T cell expansion above the normal range post-SARS-CoV-2. Yet, in participants with HIV suppressed by antiretroviral therapy (ART), CD8 expansion was associated with milder COVID-19 disease. There were multiple differences in T cell, B cell, and natural killer cell correlations in PLWH compared to HIV negative participants, including lower tissue homing CXCR3+ CD8 T cells in the presence of SARS-CoV-2 RNA in PLWH but not HIV negative and a pronounced early antibody secreting cell (ASC) expansion in HIV negative but not PLWH. These changes were COVID-19 associated: low CXCR3 correlated with increased COVID-19 disease severity across groups, and high ASC correlated with increased disease severity in HIV negative participants and waned when SARS-CoV-2 was cleared. Despite the altered response of immune cell subsets, COVID-19 disease in PLWH was mostly mild and similar to HIV negative participants. This likely reflects the heterogeneity of an effective COVID-19 immune response. Whether the differences in immune cell dynamics in PLWH will lead to different long-term consequences or compromise vaccination is yet to be determined.
Lustig Gila、Muema Daniel、Mazibuko Matilda、Gosnell Bernadett I.、Bernstein Mallory、Krause Robert、Rodel Hylton、Mthabela Ntombifuthi、Sigal Alex、Khan Khadija、COMMIT-KZN Team、Moosa Mahomed-Yunus S.、Gazy Inbal、Kl?verpris Henrik、Zungu Yenzekile、de Oliveira Tulio、Ganga Yashica、Wong Emily、Cele Sandile、Hanekom Willem、Karim Farina、Ndung?ˉu Thumbi、Leslie Alasdair、Ramjit Dirhona
Centre for the AIDS Programme of Research in South AfricaAfrica Health Research Institute||School of Laboratory Medicine and Medical Sciences, University of KwaZulu-NatalAfrica Health Research InstituteDepartment of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-NatalAfrica Health Research InstituteAfrica Health Research Institute||School of Laboratory Medicine and Medical Sciences, University of KwaZulu-NatalAfrica Health Research Institute||Division of Infection and Immunity, University College LondonAfrica Health Research InstituteAfrica Health Research Institute||School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal||Max Planck Institute for Infection BiologyAfrica Health Research InstituteDepartment of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-NatalSchool of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal||KwaZulu-Natal Research Innovation and Sequencing PlatformAfrica Health Research Institute||Division of Infection and Immunity, University College London||Department of Immunology and Microbiology, University of CopenhagenAfrica Health Research InstituteKwaZulu-Natal Research Innovation and Sequencing PlatformAfrica Health Research InstituteAfrica Health Research Institute||Division of Infectious Diseases, University of Alabama at BirminghamAfrica Health Research Institute||School of Laboratory Medicine and Medical Sciences, University of KwaZulu-NatalAfrica Health Research Institute||Division of Infection and Immunity, University College LondonAfrica Health Research Institute||School of Laboratory Medicine and Medical Sciences, University of KwaZulu-NatalAfrica Health Research Institute||Division of Infection and Immunity, University College London||HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal||Max Planck Institute for Infection BiologyAfrica Health Research Institute||Division of Infection and Immunity, University College LondonAfrica Health Research Institute
医药卫生理论医学研究方法基础医学
Lustig Gila,Muema Daniel,Mazibuko Matilda,Gosnell Bernadett I.,Bernstein Mallory,Krause Robert,Rodel Hylton,Mthabela Ntombifuthi,Sigal Alex,Khan Khadija,COMMIT-KZN Team,Moosa Mahomed-Yunus S.,Gazy Inbal,Kl?verpris Henrik,Zungu Yenzekile,de Oliveira Tulio,Ganga Yashica,Wong Emily,Cele Sandile,Hanekom Willem,Karim Farina,Ndung?ˉu Thumbi,Leslie Alasdair,Ramjit Dirhona.HIV infection alters SARS-CoV-2 responsive immune parameters but not clinical outcomes in COVID-19 disease[EB/OL].(2025-03-28)[2025-05-06].https://www.medrxiv.org/content/10.1101/2020.11.23.20236828.点此复制
评论